Lung injury and respiratory failure is a major causes of death after HCT.
Although the BMT-CTN has a focused agenda on GVHD, reduction of lung toxicities will be important to improve outcomes.
NHLBI should encourage researched from the... more »
What are the regional variations in cellular and molecular characteristics (from epigenetics to microbiome) in the lung, and what controls these variations?
Both adults and children have significant morbidity and mortality due to lung injury, but have different etiologies and outcomes. It is possible that the underlying pathobiology in the two groups is different. There are no targeted therapies for lung injury, indicating that the cause is still not understood.
What are the critical mechanisms that account for progression from reversible to irreversible ischemia and reperfusion injury?
Will adaptive trial design improve clinical research for acute lung injury?
Microvascular ischemia is common, particularly in the setting of critical illness. We need better ways to evaluate, diagnose and treat these conditions, whether they relate to microvascular myocardial ischemia, as a primary diagnosis of complication of other acute illness, or non-myocardial ischemia during the course of surgery, injury, infection or acute illness.
Understanding injury, regeneration and repair of the developing lung.
There is a need to employ new molecular tools to delineate the difference between beneficial and uncontrolled shock-induced hypothermia, because data on hypothermia and hemostasis are incomplete or lacking, especially on the duration, depth and type of hypothermia.
availability of targeted resource grant funding